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Macrolides Are Associated with a Better Survival
Rate in Patients Hospitalized with Community-Acquired
But Not Healthcare-Associated Pneumonia
Colleen McEvoy,1 Scott T. Micek,2 Richard M. Reichley,3 Jason Kan,2 Alex Hoban,1
Justin Hoffmann,4 Andrew F. Shorr,5 and Marin H. Kollef1

Abstract

Background: Macrolide-based treatment has been associated with survival benefit in patients hospitalized with
community-acquired pneumonia (CAP). However, the influence of macrolide therapy in all patients hospitalized with pneumonia, including healthcare-associated pneumonia (HCAP), is unclear.
Methods: Analysis of a retrospective single-center cohort.
Results: Community-acquired pneumonia was present in 220 (22.5%) of all patients with pneumonia admitted
through the emergency department of Barnes-Jewish Hospital, and HCAP was present in 757. Macrolide-based
treatment was administered to 411 patients (42.1%). These patients were more likely to have CAP than were
patients not receiving macrolide-based therapy (35.3% vs. 13.3%; p < 0.001) and had lower scores on the
CURB-65 tool, a measure of the severity of illness (2.4 – 1.5 vs. 3.1 – 1.3; p < 0.001). Patients receiving
macrolides also had a lower hospital mortality rate in univariable analysis (12.7% vs. 27.2%; p < 0.001). A
propensity score analysis showed that macrolide-based treatment was associated with a lower in-hospital
mortality rate (adjusted odds ratio [AOR] 0.67; 95% confidence interval [CI] 0.54–0.81; p = 0.043). Separate
propensity score analyses of patients with CAP (AOR 0.20; 95% CI 0.11–0.34; p = 0.003) and HCAP (AOR
0.81; 95% CI 0.65–1.01; p = 0.337) produced discordant findings.
Conclusions: Macrolide-based treatment was associated with better survival in patients hospitalized with
pneumonia. The survival advantage appeared predominantly among patients with CAP.

P

neumonia is one of the leading causes of death and
the leading cause of hospitalization attributable to an
infectious disease [1,2]. For patients hospitalized with
pneumonia, 30-d mortality rates are as high as 23%, and
annual expenditures in the United States for the treatment of
these infections are $8–$10 billion [1,3]. Patients hospitalized with pneumonia generally are categorized as having
either community-acquired pneumonia (CAP) or healthcareassociated pneumonia (HCAP) on the basis of their exposure
to the healthcare system.
Previous studies have suggested that morbidity and mortality rates are reduced with macrolide-based regimens in
patients with CAP [4–7]. We are unaware of any analyses
examining the impact of macrolide-based treatment in patients hospitalized with pneumonia that included both pa-

tients with CAP and those with HCAP. The increasing
population of patients hospitalized with HCAP highlights the
importance of determining the clinical significance or lack
thereof of macrolide therapy for this important subgroup of
patients [8]. Therefore, we conducted a study to determine
whether macrolide-based treatment is associated with a survival benefit in a consecutive group of patients hospitalized
with pneumonia of either type.
Patients and Methods
Study Design

A retrospective cohort analysis was performed of all patients admitted through the emergency department to BarnesJewish Hospital (1,250 beds) with a diagnosis of pneumonia
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over a 12-mo period ( January–December 2010). We excluded patients transferred from other hospitals directly to the
wards or to the intensive care unit (ICU). This study was
approved by the Washington University School of Medicine
Human Studies Committee.
Data Source

One of the investigators (RMR) identified potential study
patients by the presence of either a primary or secondary
International Classification of Diseases-9-CM code indicative of pneumonia. Patients with pneumonia were further
identified using the definitions described below. The initial
study database was constructed by merging patient-specific
data from the automated hospital medical records and microbiology and pharmacy databases of the hospital.
Definitions

Diagnosis of pneumonia necessitated both signs and
symptoms of infection (i.e., elevated white blood cell count
or > 10% band forms; fever or hypothermia; chest radiograph
revealing an infiltrate[s]). One investigator (MHK), blinded
to the determination of pneumonia, reviewed the chest images. The diagnosis of a bacterial infection required a positive
culture of blood, pleural fluid, sputum, or the lower airways.
We also considered a positive urinary antigen test for either
Streptococcus pneumoniae or Legionella spp. as documentation of a bacterial infection.
A HCAP was defined as pneumonia in a patient admitted
to the hospital with one of the following risk factors: (1)
Residence in a nursing home, rehabilitation hospital, or other
long-term nursing facility; (2) hospitalization within the
immediately preceding 12 mo; or (3) receiving outpatient
hemodialysis, peritoneal dialysis, wound care, or infusion
therapy necessitating regular visits to a hospital-based clinic.
We also determined the presence of an immunocompromised
state, defined as being seropositive for the human immunodeficiency virus (HIV), active malignancy undergoing chemotherapy, or treatment with immunosuppressants (i.e.,
10 mg of prednisone or equivalent or a similar agent daily for
at least 30 d).
Antimicrobial treatment was classified as being appropriate if the initially prescribed antibiotic regimen was active
against the identified pathogen, as judged by in vitro susceptibility testing. Patients with pneumonia attributed to
Legionella spp. were defined as receiving appropriate treatment if their initial antibiotic regimen included a macrolide
(e.g., azithromycin) or respiratory quinolone (e.g., moxifloxacin). Appropriate antimicrobial treatment had to be
prescribed within 24 h of hospital admission.
Statistics

Discrete variables were expressed as counts (percentage)
and continuous variables as mean – standard deviation (SD)
or medians with the 25th–75th percentile interquartile range
(IQR). The X2 test or Fisher exact test was used for categorical variables and the Student t-test or the Mann–Whitney
U test for continuous variables as appropriate. Multivariable
stepwise logistic regression analysis was used to assess the
impact of explanatory variables on outcome (in-hospital
death). To avoid spurious associations, only variables with a
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relation in univariable analysis (p £ 0.1) or a potential plausible relation to the outcome were entered in the logistic
regression models.
In addition, the effectiveness of macrolide therapy on the
hospital mortality rate was estimated further using propensity
scores. These scores were estimated by fitting a logistic regression model. The covariates included in the propensity
score model were those measured previous to macrolide
treatment having a potential impact on outcome: Age, CURB65 score, Charlson comorbidity score, gender, chronic obstructive pulmonary disease (COPD), congestive heart failure,
chronic renal disease, hematologic or malignant disease, solid
tumor, diabetes mellitus, immunosuppression including the
presence of human immunodeficiency virus (HIV), dementia,
recent hospitalization, admission from a nursing home, and
antibiotic treatment within the previous 90 d. Propensity score
quintiles were derived, and boxplots of the estimated propensity scores for macrolide-treated and -untreated patients
within each quintile of the propensity scores were plotted to
assess the validity of the analysis. Finally, we fitted a logistic
model for in-hospital death, including as covariates the propensity score and macrolide treatment. Results are presented as
adjusted odds ratios (AORs) and 95% confidence intervals
(CIs). Additionally, we repeated these analyses for the subgroups of patients with CAP and HCAP. Finally, we performed a logistic regression analysis for the subgroup of
patients receiving macrolide therapy to determine the factors
associated with survival. For all analyses, p values < 0.05 were
considered significant. We used SPSS for Windows 19.0
(SPSS, Chicago, IL) for all analyses.
Results

Nine hundred seventy-seven consecutive patients with
pneumonia admitted to Barnes-Jewish Hospital in 2010 were
included in the study. The mean age of the patients was
60.5 – 16.9 y (range 17–102 y) with 544 men (55.7%) and
433 women. Approximately three-quarters of the patients
were hospitalized with HCAP (77.5%), and the remainder
had CAP. The average CURB-65 score, a measure of illness
severity was 2.8 – 1.4 (median 3.0; 25th and 75th percentiles
2.0 and 4.0).
Macrolide-based therapy was administered to 411 patients (42.1%). Clarithromycin was given to one patient and
azithromycin to 410 patients (99.8%). Patients receiving
macrolide-based therapy were statistically younger, were
more likely to be African-American, had lower CURB-65
and Charlson comorbidity scores, were less likely to have
dementia or be in a bed-bound state, and were less likely to
require hemodialysis than patients who did not receive a
macrolide-based regimen (Table 1). Patients treated with
macrolides were also significantly less likely to be immunosuppressed, have had a recent hospitalization, have
been admitted from a nursing home, and have HCAP than
patients not treated with a macrolide. The number of HCAP
risk factors was statistically lower for patients receiving
macrolides (1.3 – 1.2 vs. 2.0 – 1.1; p < 0.001). Hospital
length of stay was significantly shorter for patients receiving macrolide-based therapy (10.2 – 12.3 d vs. 12.7 – 15.0
d; p = 0.005).
The pathogens associated most commonly with pneumonia were methicillin-resistant Staphyloccocus aureus
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Table 1. Baseline Characteristics of Patients
Macrolide No Macrolide
Treatment
Treatment
(n = 411)
(n = 566)
p value
Age (years – standard 58.0 – 17.0
deviation [SD])
Male (%)
225 (54.7)
Race (%)
White
209 (50.9)
African-American
196 (47.7)
Other
6 ( 1.5)
CURB-65 Score – SDa 2.4 – 1.5
Charlson Comorbidity 4.7 – 3.4
Score – SD
Congestive heart
137 (33.3)
failure (%)
Dementia (%)
8 ( 1.9)
COPD (%)
210 (51.1)
End-stage liver
7 ( 1.7)
disease (%)
Diabetes mellitus (%) 21 ( 5.1)
Bed-bound state (%)
12 ( 2.9)
Chronic kidney
55 (13.4)
disease (%)
Hemodialysis (%)
22 ( 5.4)
Solid cell tumor (%)
25 ( 6.1)
Lymphoma (%)
26 ( 6.3)
Leukemia (%)
17 ( 4.1)
HIV infection (%)
15 ( 3.6)
107 (26.0)
Other
immunosuppression
(%)
HCAP (%)
266 (64.7)
Recent
218 (53.0)
hospitalization (%)
Admitted from a
35 ( 8.5)
nursing home (%)
Number of HCAP risk factors and
immunosuppression (%)
0
145 (35.3)
1
90 (21.9)
2
104 (25.3)
3
62 (15.1)
4
10 ( 2.4)
5
0

62.4 – 16.6

< 0.001

319 (56.4)

0.616

339 (59.9)
225 (39.8)
2 ( 0.4)
3.1 – 1.3
6.0 – 3.4

0.005
< 0.001
< 0.001

195 (34.5)

0.715

36 (16.4)
302 (53.4)
19 ( 3.4)

0.001
0.485
0.113

46 ( 8.1)
45 ( 8.0)
102 (18.0)

0.065
0.001
0.051

50
53
41
26
9
207

( 8.8)
( 9.4)
( 7.2)
( 4.6)
( 1.6)
(36.6)

0.040
0.062
0.575
0.731
0.040
< 0.001

491 (86.7)
422 (74.6)

< 0.001
< 0.001

138 (24.4)

< 0.001

75
119
165
173
32
2

(13.3)
(21.0)
(29.2)
(30.6)
( 5.7)
( 0.4)

< 0.001

a
CURB-65 = Confusion new onset, Urea > 19 mg/dL, Respiratory
rate ‡ 30 breaths/min, Blood pressure < 90 mm Hg systolic or £ 60 mm
Hg diastolic, age ‡ 65 years.
Abbreviations: COPD = chronic obstructive pulmonary disease;
HCAP = healthcare-acquired pneumonia; HIV = human immunodeficiency virus.

( MRSA)(22.7%), S. pneumoniae (19.1%), Pseudomonas
aeruginosa (19.1%), methicillin-sensitive S. aureus (MSSA)
(14.1%), and Haemophilus influenzae (8.0%) (Table 2). Patients receiving macrolide-based therapy were significantly
more likely to be infected with Legionella spp., Haemophilus
influenzae, S. pneumoniae, and other Streptococcus species
than patients not receiving a macrolide. Patients not receiving
macrolide-based treatment were more likely to be infected
with Escherichia coli, Klebsiella pneumoniae, MRSA, and
Pseudomonas aeruginosa. Polymicrobial infection occurred
in 139 patients (14.2%) and was less common in patients
treated with macrolides. Secondary bacteremia developed in

Table 2. Pathogens Associated with
Pneumonia (No. [%])
Macrolide
Treatment
(n = 411)
Achromobacter spp.
2 ( 0.5)
Acinetobacter spp.
9 ( 2.2)
Burkholderia spp.
0
Citrobacter spp.
0
EBSL-producing
Enterobacteriaceae
2 ( 0.5)
Enterobacter spp.
6 ( 1.5)
Escherichia coli
10 ( 2.4)
Haemophilus
46 (11.2)
influenzae
Klebsiella
12 ( 2.9)
pneumoniae
Legionella spp.
11 ( 2.7)
Moraxella spp.
9 ( 2.2)
Morganella spp.
0
MRSA
74 (18.0)
MSSA
63 (15.3)
Mycoplasma
3 ( 0.7)
pneumoniae
Proteus spp.
5 ( 1.2)
Providencia spp.
0
Pseudomonas
46 (11.2)
aeruginosa
Serratia marcescens
2 ( 0.5)
4 ( 1.0)
Stenotrophomonas
maltophilia
Streptococcus
126 (30.7)
pneumoniae
Other Streptococcus
25 ( 6.1)
spp.
Polymicrobial
40 ( 9.7)
infection
Positive blood
136 (33.1)
culture

No Macrolide
Treatment
(n = 566)
P value
9
38
1
4

(
(
(
(

1.6)
6.7)
0.2)
0.7)

0.132
0.001
1.000
0.143

5
13
43
32

(
(
(
(

0.9)
2.3)
7.6)
5.7)

0.705
0.350
< 0.001
0.002

43 ( 7.6)

0.002

1
11
4
148
75
0

( 0.2)
( 1.9)
( 0.7)
(26.1)
(13.3)

0.001
0.788
0.143
0.003
0.357
0.074

17 ( 3.0)
2 ( 0.4)
141 (24.9)

0.063
0.512
< 0.001

11 ( 1.9)
10 ( 1.8)

0.086
0.416

61 (10.8)

< 0.001

15 ( 2.7)

0.008

99 (17.5)

0.001

200 (35.3)

0.466

Abbreviations: ESBL = extended-spectrum b-lactamase; MRSA =
methicillin-resistant Staphylococcus aureus; MSSA = methicillinsensitive S. aureus.

336 patients (34.4%) with similar occurrences in patients
treated with and those not receiving a macrolide drug.
The overall hospital mortality rate was 21.1% (n = 206).
The rate was lower among macrolide-treated patients (12.7%
vs. 27.2%; p < 0.001). In-hospital death was associated with
older age, greater CURB-65 and Charlson comorbidity
scores, whereas race, end-stage liver disease, hemodialysis,
immunosuppression, recent hospitalization, admission from
a nursing home, and HCAP (Table 3). The number of HCAP
risk factors was statistically greater among nonsurvivors
(2.0 – 1.2 vs. 1.6 – 1.2; p < 0.001). The hospital length of stay
was similar for nonsurvivors and survivors (12.2 – 19.6 d
vs. 11.5 – 12.1 days; p = 0.495). Kaplan-Meier curve analysis
demonstrated that hospital survival was significantly greater
for macrolide-treated patients (both CAP and HCAP), and the
survival difference was more pronounced for the CAP subgroup (Fig. 1). There was no difference in survival of the
HCAP patients receiving and not receiving macrolide-based
therapy.
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Table 3. Predictors of In-Hospital Death
Nonsurvivors
(n = 206)

Survivors
(n = 771)

p
value

Age (years – standard
64.5 – 15.6 59.5 – 17.1 < 0.001
deviation [SD])
Male (%)
117 (56.8) 427 (55.4)
0.717
Race (%)
White
132 (64.1) 416 (54.0)
0.013
African-American
71 (34.5) 350 (45.4)
Other
3 ( 1.5)
5 ( 0.6)
CURB-65 Score – SD
3.8 – 0.9
2.6 – 1.5 < 0.001
Charlson comorbidity
6.9 – 3.5
5.1 – 3.4 < 0.001
score – SD
Congestive heart
76 (36.9) 256 (33.2)
0.321
failure (%)
Dementia (%)
13 ( 6.3)
31 ( 4.0)
0.159
COPD (%)
100 (48.5) 412 (53.4)
0.212
End-stage liver
15 ( 7.3)
11 ( 1.4) < 0.001
disease (%)
Diabetes (%)
18 ( 8.7)
49 ( 6.4)
0.229
Bed-bound state (%)
7 ( 3.4)
50 ( 6.5)
0.093
Chronic kidney
43 (20.9) 114 (14.8)
0.035
disease (%)
Hemodialysis (%)
25 (12.1)
47 ( 6.1)
0.003
Solid tumor (%)
19 ( 9.2)
59 ( 7.7)
0.460
Lymphoma (%)
17 ( 8.3)
50 ( 6.5)
0.373
Leukemia (%)
13 ( 6.3)
30 ( 3.9)
0.133
HIV (%)
6 ( 2.9)
18 ( 2.3)
0.634
Other
82 (39.8) 232 (30.1)
0.008
immunosuppression
(%)
HCAP
180 (87.4) 577 (74.8) < 0.001
Recent hospitalization 155 (75.2) 485 (62.9)
0.001
Admitted from
47 (22.8) 126 (16.3)
0.031
nursing home
Number of HCAP risk factors and immunosuppression
0
26 (12.6) 194 (25.2) < 0.001
1
47 (22.8) 162 (21.0)
2
52 (25.2) 217 (28.1)
3
70 (34.0) 165 (21.4)
4
9 ( 4.4)
33 ( 4.2)
5
2 ( 1.0)
0
a
CURB-65 = Confusion new onset, Urea > 19 mg/dL, Respiratory
rate ‡ 30 breaths/min, Blood pressure < 90 mm Hg systolic or
£ 60 mm Hg diastolic, age ‡ 65 y.
Abbreviations: COPD = chronic obstructive pulmonary disease;
HCAP = healthcare-acquired pneumonia; HIV = human immunodeficiency virus.

A logistic regression analysis adjusted for severity of illness (CURB-65, Charlson comorbidity score) and potential
confounding factors (congestive heart failure, COPD, dementia, end-stage liver disease, diabetes, solid tumor, lymphoma, leukemia, HIV infection, age, gender, recent
hospitalization, admission from a nursing home, immunosuppression, and previous antibiotic administration) found
that macrolide use was significantly associated with survival
(AOR 0.63; 95% CI 0.52–0.77; p = 0.021). Similarly, the
propensity score analysis found macrolide use to be significantly associated with a lower mortality rate (AOR 0.67; 95%
CI 0.54–0.81; p = 0.043). The overlapping of the propensity
scores for macrolide-treated and non-macrolide-treated patients within each propensity score quintile reinforced the

FIG. 1. Kaplan-Meier curves for patients with community-acquired pneumonia (CAP) and healthcare-associated
pneumonia (HCAP) receiving macrolide-based (broken line)
and non-macrolide-based (solid line) regimens.
validity of the propensity score analysis (Fig. 2). Propensity
score analysis for the subgroup of patients with CAP demonstrated macrolide use to be associated with a lower mortality rate (AOR 0.20; 95% CI 0.11–0.34; p = 0.003);
however, for the subgroup with HCAP, there was no demonstrable effect of macrolide treatment on the mortality rate
(AOR 0.81; 95% CI 0.65–1.01; p = 0.337).
A logistic regression analysis of the subgroup of patients
receiving macrolide therapy identified only two independent
predictors of a lower mortality rate despite including all
identified co-morbidities and the individual HCAP risks.
Absence of mechanical ventilation (AOR 0.33; 95% CI 0.25–
0.44; p < 0.001) and lower CURB-65 scores (one-point decrements)(AOR 0.52; 95% CI 0.44–0.61; p < 0.001) were independently associated with a lower mortality rate among
macrolide-treated patients (Hosmer-Lemeshow goodness-offit p = 0.783).
Discussion

We demonstrated that the use of macrolide-based therapy
was associated with a lower risk of in-hospital death among
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FIG. 2. Box plots of propensity score quintiles (Q) for
patients with and without macrolide-based therapy.
consecutive patients admitted to the hospital with pneumonia. However, our sensitivity analysis suggests that this
benefit is seen primarily in patients with CAP, not those with
HCAP. Not surprisingly, the distribution of pathogens in
patients with CAP and HCAP differed, with S. pneumoniae
being the predominant bacterium isolated in patients with
CAP and S. aureus and P. aeruginosa being the most common bacterial pathogens associated with HCAP. We also
found that among patients treated with macrolides, only
mechanical ventilation and CURB-65 scores predicted the
risk of death.
Previous studies have demonstrated the potential benefit of
macrolide-based therapy in patients with CAP. Asadi et al.
conducted a meta-analysis that included 23 studies and
137,574 patients with CAP [7]. Overall, macrolide use was
associated with a statistically significant mortality reduction
compared with nonmacrolide use. However, there was no
survival advantage, and study heterogeneity was reduced
when analyses were restricted to randomized trials or to patients treated with guideline-concordant antibiotics (macrolide/beta-lactam or respiratory fluoroquinolones). Another
recent meta-analysis reviewed 28 studies of CAP, with the
main objective being to estimate the mortality rate and the
proportion with treatment failure using regimens containing
atypical antibiotic coverage compared with those that had
typical coverage only [9]. There was no difference in the
mortality rates between the atypical-drug arm and the nonatypical arm. The atypical arm showed an insignificant trend
toward greater clinical success and a significant advantage in
bacterial eradication, which disappeared when evaluating
methodologically high-quality studies alone. Taken together,
these meta-analyses, as well as other clinical studies, suggest
that guideline-based coverage of atypical pathogens in CAP
may be most important in determining clinical outcomes,
including the mortality rate and bacterial eradication [7,9,10].
Other investigators have found mixed results with the use
of macrolides in the treatment of community-based respiratory infections. Martı́n-Loeches et al. used a propensity score
analysis and found that macrolide-based treatment was not
associated with a better survival rate in critically ill patients
with viral pneumonia attributed to influenza virus H1N1 [11].
However, recent studies in COPD [12], cystic fibrosis
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[13,14], bronchiolitis obliterans syndrome [15], and asthma
[16] suggest that macrolides may confer benefit to patients
with community-based respiratory illnesses that are at least
partially attributed to respiratory infections for their pathogenesis. In addition to their antimicrobial properties,
macrolides have been believed to benefit patients with inflammatory lung diseases, including CAP, through antiinflammatory mechanisms. Azithromycin significantly
reduces airway neutrophilia and interleukin-8 mRNA expression [17]. The anti-inflammatory and immunomodulatory activity of macrolides purportedly contribute to their
successful use as therapeutic agents for chronic lung diseases, including cystic fibrosis and diffuse panbronchiolitis
[18].
Recent increasing rates of macrolide resistance in S.
pneumoniae have brought into question the overall utility of
this class of antibiotics for use in CAP [19]. However,
macrolides have antimicrobial activity against P. aeruginosa in eukaryotic media through increased uptake and
reduced efflux of the drug despite high minimum inhibitory
concentrations (MICs) on conventional media (cation-adjusted Mueller–Hinton broth) [20]. Despite these observations, the reported beneficial influence of macrolide therapy
on outcomes in acute pneumonia is still observed primarily
in CAP [7]. The potential antimicrobial influence of macrolides on P. aeruginosa may explain, in part, their efficacy
in patients with cystic fibrosis and other chronic lung diseases [13,14].
Our current study has several major limitations. First, we
restricted our analysis to patients with microbiologically
confirmed bacterial infection. This likely contributed to the
smaller number of patients with CAP compared with HCAP
[21]. We have shown previously that patients with culturenegative HCAP do as well with traditional CAP treatment as
with treatment targeting HCAP [22]. It is possible that had we
included culture-negative patients in our study, we might
have seen a mortality benefit with macrolide therapy in patients with HCAP. Moreover, it is possible that some of our
positive cultures from the respiratory tract reflected colonization rather than true infection. This seems to be a lesser
concern, however, given the adjudication of the radiographic
criteria and the relatively large percentage of patients with
concomitant positive blood cultures. Second, the criteria for
HCAP are somewhat arbitrary and have been disputed as
markers of antibiotic resistance in patients presenting with
pneumonia [23]. Third, we modified our criteria for HCAP
from the 2005 American Thoracic Society/Infectious Disease
Society of America guidelines by including patients with
hospitalization up to one year earlier [24]. This was done
because of the limited number of good-quality studies reporting on the relation of timing of prior hospitalization and
antibiotic exposure to subsequent development of antibioticresistant infections and the results of a recent meta-analysis
suggesting that the effects of previous antibiotic prescription
on resistance emergence were conspicuous for as long as
12 mo after exposure [25].
It is important to note that we did not evaluate systematically for concomitant viral infection. Given the possibility
that some patients with acute viral infections will present
with pneumonia, we may have diluted the influence of
macrolide therapy, especially among patients with HCAP,
given the recent Spanish experience [11]. It also is possible
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that the difference in outcomes associated with macrolide
therapy between patients with CAP and those with HCAP
was attributable to some underdetermined confounding factor. For example, there were more patients with immunosuppression in the HCAP group, which may have influenced
the patients’ response to macrolide therapy. Finally, all
nursing home patients do not appear to be the same. Previous
investigators have shown that among nursing home patients,
prior antibiotic administration and daily living activity are the
best predictors of infection with HCAP pathogens [26]. However, we captured the presence of a bed-bound state and prior
antibiotic exposure in our analysis, so our assessment of the
nursing home patients should have been complete in this regard.
In conclusion, our data suggest that macrolide therapy is
most effective in patients with CAP, and we could not
demonstrate any influence of these drugs on the survival of
patients with HCAP. This suggests that the use of macrolides
in pneumonia should be based on the published guidelines
that recommend their use when a clinical or epidemiologic
suspicion of infection with atypical pathogens exists, primarily in patients with CAP [3]. The clinical use of risk
factors to identify patients at risk for HCAP may assist clinicians in detecting patients who are unlikely to benefit from
macrolide therapy.

MCEVOY ET AL.

9.

10.

11.

12.
13.

14.

Author Disclosure Statement

15.

The authors have no conflicts of interest in relation to this
work. Dr. Kollef’s efforts were supported by the BarnesJewish Hospital Foundation.

16.

References

1. File TM Jr, Marrie TJ. Burden of community-acquired
pneumonia in North American adults. Postgrad Med 2010;
122:130–141.
2. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and
timing of 30-day readmissions after hospitalization for
heart failure, acute myocardial infarction, or pneumonia.
JAMA 2013;309:355–363.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious
Diseases Society of America/American Thoracic Society
consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007;
44(Suppl 2):S27–S72.
4. Martı́nez JA, Horcajada JP, Almela M, et al. Addition of a
macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin
Infect Dis 2003;36:389–395.
5. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics
for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466–473.
6. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of
macrolide therapy on mortality for patients with severe
sepsis due to pneumonia. Eur Respir J 2009;33:153–159.
7. Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with communityacquired pneumonia: A systematic review and meta-analysis.
Clin Infect Dis 2012;55:371–380.
8. Kollef MH, Morrow LE, Baughman RP, et al. Health careassociated pneumonia (HCAP): A critical appraisal to
improve identification, management, and outcomes. Pro-

17.

18.
19.

20.

21.
22.
23.
24.

ceedings of the HCAP Summit. Clin Infect Dis 2008;
46(Suppl 4):S296–S334.
Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric
antibiotic coverage of atypical pathogens for communityacquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012;9:CD004418.
Asadi L, Eurich DT, Gamble JM, et al. Impact of guidelineconcordant antibiotics and macrolide/b-lactam combinations in 3203 patients hospitalized with pneumonia:
Prospective cohort study. Clin Microbiol Infect 2013;19:
257–264.
Martı́n-Loeches I, Bermejo-Martin JF, Vallés J, et al.
Macrolide-based regimens in absence of bacterial coinfection in critically ill H1N1 patients with primary viral
pneumonia. Intensive Care Med 2013;39:693–702.
Albert RK, Connett J, Bailey WC, et al. Azithromycin for
prevention of exacerbations of COPD. N Engl J Med
2011;365:689–698.
Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of
azithromycin on pulmonary function in patients with cystic
fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2010;303:1707–1715.
Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized
controlled trial. JAMA 2003;290:1749–1756.
Jain R, Hachem RR, Morrell MR, et al. Azithromycin is
associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart
Lung Transplant 2010;29:531–537.
Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma
(AZISAST): A multicentre randomised double-blind placebocontrolled trial. Thorax 2013;68:322–329.
Verleden GM, Vanaudenaerde BM, Dupont LJ, Van
Raemdonck DE. Azithromycin reduces airway neutrophilia
and interleukin-8 in patients with bronchiolitis obliterans
syndrome. Am J Respir Crit Care Med 2006;174:566–570.
Spagnolo P, Fabbri LM, Bush A. Long-term macrolide
treatment for chronic respiratory disease. Eur Respir J 2012
(Epub ahead of print).
Low DE. What is the relevance of antimicrobial resistance
on the outcome of community-acquired pneumonia caused
by Streptococcus pneumoniae? (Should macrolide monotherapy be used for mild pneumonia?). Infect Dis Clin
North Am 2013;27:87–97.
Buyck JM, Plésiat P, Traore H, et al. Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological
fluids due to decreased expression of oprM and increased
outer-membrane permeability. Clin Infect Dis 2012;55:
534–542.
Blaschke AJ. Interpreting assays for the detection of
Streptococcus pneumoniae. Clin Infect Dis 2011;52(Suppl
4):S331–S337.
Labelle AJ, Arnold H, Reichley RM, et al. A comparison of
culture-positive and culture-negative health-care-associated
pneumonia. Chest 2010;137:1130–1137.
Ewig S, Welte T, Torres A. Is healthcare-associated
pneumonia a distinct entity needing specific therapy? Curr
Opin Infect Dis 2012;25:166–175.
American Thoracic Society, Infectious Diseases Society of
America. Guidelines for the management of adults with
hospital-acquired, ventilator-associated, and healthcare-

MACROLIDES AND PNEUMONIA

associated pneumonia. Am J Respir Crit Care Med 2005;
171:388–416.
25. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance
in individual patients: Systematic review and meta-analysis.
BMJ 2010;340:c2096.
26. El Solh AA, Pietrantoni C, Bhat A, et al. Indicators of
potentially drug-resistant bacteria in severe nursing homeacquired pneumonia. Clin Infect Dis 2004;39:474–480.

289

Address correspondence to:
Dr. Marin H. Kollef
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine
660 South Euclid Ave. Campus Box 8052
St. Louis, MO 63110
E-mail: mkollef@dom.wustl.edu

